≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Carcinoma in situ of larynx

DOID Endpoint Browser

CD2_INSITU_LARYNX

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

  • not C3_LARYNX
519234

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D02.0&
  • Hospital discharge: ICD-9 — 2310
  • Cause of death: ICD-10 — D02.0&
  • Cause of death: ICD-9 — 2310
  • Cancer registry: Topography ICD-O-3 — C32
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 2

3 out of 7 registries used, show all original rules.

55

4. Check minimum number of events

None

55

5. Include endpoints

None

55

6. Filter based on genotype QC (FinnGen only)

54

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D02
Name in latin
Carcinoma in situ bronchi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 54 12 42
Unadjusted period prevalence (%) 0.02 0.00 0.02
Median age at first event (years) 65.68 47.82 70.79

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
55
Matched controls
550
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
295.7
31.2
29
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
33.0
22.3
30
19
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
152.8
20.1
20
*
D02.0
ICD-10 Finland
Carcinoma in situ: Larynx
+∞
20.0
18
*
C32.0
ICD-10 Finland
Malignant neoplasm: Glottis
130.3
17.8
18
*
DQA10
NOMESCO Finland
Biopsy of larynx
239.9
17.6
17
*
C320, 8077, 2
ICD-O-3
+∞
16.5
15
*
J38.3
ICD-10 Finland
Other diseases of vocal cords
47.9
14.5
17
5
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
183.5
14.2
14
*
8070/2-C32.0
ICD-O-3
Squamous cell carcinoma in situ, NOS, of glottis
+∞
13.0
12
*
UDQ22
NOMESCO Finland
Microlaryngoscopy
61.2
12.6
14
*
ZXC10
NOMESCO Finland
Use of laser
30.5
10.9
14
6
J37.0
ICD-10 Finland
Chronic laryngitis
20.0
10.2
15
10
EP1AE
NOMESCO Finland
Neck ultrasound examination
16.8
10.2
16
13
WX734
NOMESCO Finland
JET-ventilation
+∞
8.5
8
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.5
7.8
20
52
2310A
ICD-9 Finland
Carcinoma in situ of respiratory system, Larynx
+∞
7.4
7
*
C32.9
ICD-10 Finland
Malignant neoplasm: Larynx, unspecified
+∞
7.4
7
*
8070/2-C32.9
ICD-O-3
Squamous cell carcinoma in situ, NOS, of larynx, NOS
+∞
6.4
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Otolaryngology
4 [38004449]
1.3e+00
3.0e+00
—
1.0e+50
4.6e+00
4.4e+00
—
cases:35.85%
controls:12.69%
cases:43.40%
controls:3.65%
—
—
cases:43.40%
controls:0.00%
cases:49.06%
controls:0.96%
cases:76.47%
controls:3.75%
—
—
19
66
34
454
23
19
30
501
—
23
0
30
520
26
5
27
515
39
19
12
487
—
Outpatient Visit
OP [9202]
2.8e-01
8.8e-01
1.8e+00
4.2e+00
1.8e+00
1.1e+00
—
cases:79.25%
controls:74.23%
cases:75.47%
controls:55.96%
cases:43.40%
controls:11.35%
cases:39.62%
controls:0.96%
cases:50.94%
controls:15.00%
cases:78.43%
controls:55.73%
—
—
42
386
11
134
40
291
13
229
23
59
30
461
21
5
32
515
27
78
26
442
40
282
11
224
—
Audiology
64 [38004489]
1.5e+00
3.1e+00
—
—
—
3.1e+00
—
cases:15.09%
controls:3.85%
cases:20.75%
controls:1.15%
—
—
—
—
—
—
cases:33.33%
controls:2.17%
—
—
8
20
45
500
11
6
42
514
—
—
—
17
11
34
495
—
Inpatient Hospital
21 [8717]
4.8e-01
4.1e-01
2.3e+00
1.0e+50
2.6e+00
1.2e+00
—
cases:50.94%
controls:39.23%
cases:16.98%
controls:11.92%
cases:18.87%
controls:2.31%
cases:11.32%
controls:0.00%
cases:20.75%
controls:1.92%
cases:29.41%
controls:10.87%
—
—
27
204
26
316
9
62
44
458
10
12
43
508
6
0
47
520
11
10
42
510
15
55
36
451
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
1.8e+00
1.7e+00
-1.0e+50
—
—
2.1e+00
—
cases:28.30%
controls:6.15%
cases:16.98%
controls:3.46%
cases:0.00%
controls:0.96%
—
—
—
—
cases:17.65%
controls:2.57%
—
—
15
32
38
488
9
18
44
502
0
5
53
515
—
—
9
13
42
493
—
Laboratory Visit
OMOP4822461 [32036]
-3.6e-02
3.8e-01
1.5e+00
3.6e+00
7.4e-01
2.8e-01
—
cases:47.17%
controls:48.08%
cases:54.72%
controls:45.19%
cases:41.51%
controls:13.65%
cases:37.74%
controls:1.54%
cases:30.19%
controls:17.12%
cases:56.86%
controls:50.00%
—
—
25
250
28
270
29
235
24
285
22
71
31
449
20
8
33
512
16
89
37
431
29
253
22
253
—
Outpatient Hospital
22 [8756]
3.9e-01
2.2e-01
2.9e+00
—
—
1.6e+00
—
cases:37.74%
controls:29.04%
cases:9.43%
controls:7.69%
cases:16.98%
controls:1.15%
—
—
—
—
cases:21.57%
controls:5.34%
—
—
20
151
33
369
5
40
48
480
9
6
44
514
—
—
11
27
40
479
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-3.4e-02
4.8e-01
2.0e+00
—
1.3e+00
3.3e-01
—
cases:43.40%
controls:44.23%
cases:49.06%
controls:37.31%
cases:35.85%
controls:6.73%
—
—
cases:26.42%
controls:9.23%
cases:50.98%
controls:42.89%
—
—
23
230
30
290
26
194
27
326
19
35
34
485
—
14
48
39
472
26
217
25
289
—
Case Management Agency
251B00000X [38004193]
-7.5e-02
3.4e-01
7.1e-01
2.8e+00
8.0e-01
5.5e-02
—
cases:66.04%
controls:67.69%
cases:67.92%
controls:60.00%
cases:39.62%
controls:24.42%
cases:20.75%
controls:1.54%
cases:41.51%
controls:24.23%
cases:62.75%
controls:61.46%
—
—
35
352
18
168
36
312
17
208
21
127
32
393
11
8
42
512
22
126
31
394
32
311
19
195
—
12 lead EKG panel
34534-8 [3044889]
-6.3e-01
2.7e-01
2.6e+00
—
—
-2.2e-01
—
cases:15.09%
controls:25.00%
cases:15.09%
controls:11.92%
cases:15.09%
controls:1.35%
—
—
—
—
cases:11.76%
controls:14.23%
—
—
8
130
45
390
8
62
45
458
8
7
45
513
—
—
6
72
45
434
—
General anesthesia, balanced
WX408 [2001310808]
8.1e-01
—
—
—
—
2.4e+00
—
cases:13.21%
controls:6.35%
—
—
—
—
—
—
—
—
cases:9.80%
controls:0.99%
—
—
7
33
46
487
—
—
—
—
5
5
46
501
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:0.99%
—
—
—
—
—
—
—
5
5
46
501
—
Medical Oncology
90 [38004507]
7.7e-01
—
-1.0e+50
—
—
2.3e+00
—
cases:9.43%
controls:4.62%
—
—
cases:0.00%
controls:0.96%
—
—
—
—
cases:31.37%
controls:4.15%
—
—
5
24
48
496
—
0
5
53
515
—
—
16
21
35
485
—
CBC panel - Blood by Automated count
58410-2 [40761511]
1.0e-02
7.0e-01
2.3e+00
—
1.1e+00
6.0e-01
—
cases:37.74%
controls:37.50%
cases:39.62%
controls:24.62%
cases:30.19%
controls:4.04%
—
—
cases:13.21%
controls:4.81%
cases:41.18%
controls:27.67%
—
—
20
195
33
325
21
128
32
392
16
21
37
499
—
7
25
46
495
21
140
30
366
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-3.3e-02
2.9e-01
2.2e+00
—
9.2e-01
2.1e-01
—
cases:41.51%
controls:42.31%
cases:39.62%
controls:32.88%
cases:33.96%
controls:5.58%
—
—
cases:16.98%
controls:7.50%
cases:45.10%
controls:39.92%
—
—
22
220
31
300
21
171
32
349
18
29
35
491
—
9
39
44
481
23
202
28
304
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-2.5e-02
2.9e-01
2.1e+00
—
9.5e-01
2.6e-01
—
cases:41.51%
controls:42.12%
cases:39.62%
controls:32.88%
cases:33.96%
controls:5.77%
—
—
cases:16.98%
controls:7.31%
cases:45.10%
controls:38.74%
—
—
22
219
31
301
21
171
32
349
18
30
35
490
—
9
38
44
482
23
196
28
310
—
MCH [Entitic mass]
28539-5 [3035941]
-2.0e-02
4.9e-01
2.0e+00
—
8.5e-01
2.9e-01
—
cases:45.28%
controls:45.77%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.04%
cases:50.98%
controls:43.68%
—
—
24
238
29
282
26
193
27
327
19
35
34
485
—
10
47
43
473
26
221
25
285
—
Platelets [#/volume] in Blood
26515-7 [3007461]
-2.7e-02
4.9e-01
2.0e+00
—
8.5e-01
2.9e-01
—
cases:45.28%
controls:45.96%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.04%
cases:50.98%
controls:43.87%
—
—
24
239
29
281
26
193
27
327
19
35
34
485
—
10
47
43
473
26
222
25
284
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-2.0e-02
4.9e-01
2.0e+00
—
8.3e-01
2.9e-01
—
cases:45.28%
controls:45.77%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.23%
cases:50.98%
controls:43.87%
—
—
24
238
29
282
26
193
27
327
19
35
34
485
—
10
48
43
472
26
222
25
284
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-2.7e-02
4.9e-01
2.0e+00
—
8.5e-01
2.9e-01
—
cases:45.28%
controls:45.96%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.04%
cases:50.98%
controls:43.87%
—
—
24
239
29
281
26
193
27
327
19
35
34
485
—
10
47
43
473
26
222
25
284
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-2.7e-02
4.9e-01
2.0e+00
—
8.3e-01
2.9e-01
—
cases:45.28%
controls:45.96%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.23%
cases:50.98%
controls:43.87%
—
—
24
239
29
281
26
193
27
327
19
35
34
485
—
10
48
43
472
26
222
25
284
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-2.7e-02
5.0e-01
2.0e+00
—
8.3e-01
2.8e-01
—
cases:45.28%
controls:45.96%
cases:49.06%
controls:36.92%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.23%
cases:50.98%
controls:44.07%
—
—
24
239
29
281
26
192
27
328
19
35
34
485
—
10
48
43
472
26
223
25
283
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-2.7e-02
4.9e-01
2.0e+00
—
8.3e-01
2.9e-01
—
cases:45.28%
controls:45.96%
cases:49.06%
controls:37.12%
cases:35.85%
controls:6.73%
—
—
cases:18.87%
controls:9.23%
cases:50.98%
controls:43.87%
—
—
24
239
29
281
26
193
27
327
19
35
34
485
—
10
48
43
472
26
222
25
284
—
Tissue Pathology biopsy report
66121-5 [40768804]
7.4e-01
1.3e+00
—
1.0e+50
—
1.8e+00
—
cases:16.98%
controls:8.85%
cases:9.43%
controls:2.69%
—
—
cases:32.08%
controls:0.00%
—
—
cases:23.53%
controls:4.74%
—
—
9
46
44
474
5
14
48
506
—
17
0
36
520
—
12
24
39
482
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-9.3e-02
5.2e-01
1.6e+00
—
1.1e+00
4.5e-01
—
cases:26.42%
controls:28.27%
cases:35.85%
controls:25.00%
cases:20.75%
controls:4.81%
—
—
cases:18.87%
controls:7.50%
cases:41.18%
controls:30.83%
—
—
14
147
39
373
19
130
34
390
11
25
42
495
—
10
39
43
481
21
156
30
350
—
EKG study
11524-6 [3013512]
8.1e-01
9.3e-01
—
—
—
1.4e+00
—
cases:15.09%
controls:7.31%
cases:11.32%
controls:4.81%
—
—
—
—
—
—
cases:21.57%
controls:6.13%
—
—
8
38
45
482
6
25
47
495
—
—
—
11
31
40
475
—
Other healthcare associate professional
Z3229 [2001311561]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
9.6e-01
—
—
—
—
—
—
cases:26.42%
controls:12.12%
—
—
—
—
—
—
—
—
—
—
—
—
14
63
39
457
—
—
—
—
—
—
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
0
7
53
513
—
—
—
0
11
51
495
—
Vertigo/dizziness
N17 [2002000728]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
Actinic keratosis
L57.0 [45591640]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
0
9
53
511
—
—
—
0
6
51
500
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
6.3e-01
—
—
—
—
—
—
cases:11.32%
controls:6.35%
—
—
—
—
—
—
—
—
—
—
—
—
6
33
47
487
—
—
—
—
—
—
antibiotics in combination with other drugs
S01AA20 [21603571]
3.5e-01
—
—
—
—
—
—
cases:11.32%
controls:8.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
43
47
477
—
—
—
—
—
—
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Extraction of multiple teeth
EBA15 [2001301927]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Pain in limb
M79.6 [45587063]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Extensive body CT
JN4BD [2001310899]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
glucosamine; oral
M01AX05 [21604002]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:4.04%
cases:0.00%
controls:2.12%
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
0
21
53
499
0
11
53
509
—
—
—
0
11
51
495
—
Exposure to unspecified factor
X59 [45756412]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
pH of Venous blood
2746-6 [3012544]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
0
5
53
515
—
—
—
0
8
51
498
—
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Prostate symptom/complaint
Y06 [2002001385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
Sick sinus syndrome
I49.5 [45562354]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
simvastatin; oral
C10AA01 [21601856]
8.7e-02
1.6e-01
—
—
—
4.1e-01
—
cases:22.64%
controls:21.15%
cases:18.87%
controls:16.54%
—
—
—
—
—
—
cases:21.57%
controls:15.42%
—
—
12
110
41
410
10
86
43
434
—
—
—
11
78
40
428
—
metoprolol and felodipine
C07FB02 [21601742]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:1.15%
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:1.19%
—
—
0
6
53
514
0
6
53
514
—
—
0
5
53
515
0
6
51
500
—
Laser discission of secondary cataract
CJB10 [2001301313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
acetylsalicylic acid; oral, parenteral, rectal
N02BA01 [21604305]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
—
—
—
—
—
0
11
51
495
—
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
ferrous glycine sulfate; oral
B03AA01 [21601080]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
53
509
—
—
—
—
—
—
hydrocortisone aceponate
D07AC16 [21602135]
2.7e-01
-1.0e+50
—
—
—
—
—
cases:11.32%
controls:8.85%
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
6
46
47
474
0
12
53
508
—
—
—
—
—
Cells panel - Urine sediment
58434-2 [40761535]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
0
6
53
514
—
—
—
0
8
51
498
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
0
7
53
513
—
—
—
0
9
51
497
—
ticagrelor; oral
B01AC24 [40252640]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Mitral (valve) insufficiency
I34.09 [2000502484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Caries of dentine
K02.1 [45548134]
3.5e-01
5.4e-01
—
—
-1.0e+50
3.5e-01
—
cases:20.75%
controls:15.58%
cases:11.32%
controls:6.92%
—
—
—
—
cases:0.00%
controls:1.35%
cases:9.80%
controls:7.11%
—
—
11
81
42
439
6
36
47
484
—
—
0
7
53
513
5
36
46
470
—
Periodontitis complex
K05.30 [2000502728]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
0
8
53
512
—
—
—
0
9
51
497
—
Gas panel - Capillary blood
24337-8 [3022313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
Chronic glaucoma with open ventricular angle
H40.13 [2000502335]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
6
53
514
0
5
53
515
—
—
—
—
—
desonide
D07AB08 [21602112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
—
Pain localized to upper abdomen
R10.1 [45568111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
—
Excessive ear wax
H81 [2002000536]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:13.21%
controls:4.81%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.96%
—
—
7
25
46
495
—
—
—
—
0
15
51
491
—
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
hydrocortisone buteprate
D07AB11 [21602115]
2.7e-01
-1.0e+50
—
—
—
—
—
cases:11.32%
controls:8.85%
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
6
46
47
474
0
12
53
508
—
—
—
—
—
methotrexate; oral, parenteral
L04AX03 [21603929]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
0
7
53
513
—
—
—
0
7
51
499
—
Use of laser
ZXC10 [2001311360]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:0.00%
—
—
—
—
—
—
—
5
0
46
506
—
zopiclone; oral
N05CF01 [21604654]
2.7e-01
1.1e+00
—
—
—
—
—
cases:11.32%
controls:8.85%
cases:13.21%
controls:4.62%
—
—
—
—
—
—
—
—
—
—
6
46
47
474
7
24
46
496
—
—
—
—
—
Aortic (valve) insufficiency
I35.1 [45572087]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
6.0e-01
—
—
—
-1.0e+50
4.7e-01
—
cases:32.08%
controls:20.58%
—
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:11.76%
controls:7.71%
—
—
17
107
36
413
—
—
—
0
5
53
515
6
39
45
467
—
mometasone
D07AC13 [21602132]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
JET-ventilation
WX734 [2001310833]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:9.43%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
48
520
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.0e-01
—
—
—
—
1.6e-01
—
cases:13.21%
controls:8.46%
—
—
—
—
—
—
—
—
cases:9.80%
controls:8.50%
—
—
7
44
46
476
—
—
—
—
5
43
46
463
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
Day surgery
ZXD20 [2001311388]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
scopolamine
A04AD01 [21600499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.50%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
13
53
507
0
5
53
515
—
—
—
0
5
51
501
—
brompheniramine, combinations
R06AB51 [21603466]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-7.1e-02
2.2e-01
8.6e-01
—
8.8e-01
1.2e-01
—
cases:37.74%
controls:39.42%
cases:33.96%
controls:29.23%
cases:9.43%
controls:4.23%
—
—
cases:11.32%
controls:5.00%
cases:37.25%
controls:34.58%
—
—
20
205
33
315
18
152
35
368
5
22
48
498
—
6
26
47
494
19
175
32
331
—
Right side
ZXA00 [2001311346]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
Hearing complaint
H02 [2002000476]
1.9e+00
-1.0e+50
—
—
—
—
—
cases:9.43%
controls:1.54%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
5
8
48
512
0
5
53
515
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
5.4e-01
—
—
—
—
—
—
cases:11.32%
controls:6.92%
—
—
—
—
—
—
—
—
—
—
—
—
6
36
47
484
—
—
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.12%
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
0
11
53
509
0
9
53
511
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
3.7e-01
—
—
-1.0e+50
3.6e-01
—
—
—
cases:9.43%
controls:6.73%
—
—
—
—
cases:0.00%
controls:2.50%
cases:11.76%
controls:8.50%
—
—
—
5
35
48
485
—
—
0
13
53
507
6
43
45
463
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
Benign neoplasm: Larynx
D14.1 [45552329]
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
cases:9.43%
controls:0.00%
cases:15.09%
controls:0.00%
cases:11.32%
controls:0.00%
cases:18.87%
controls:0.00%
cases:19.61%
controls:0.00%
—
—
—
5
0
48
520
8
0
45
520
6
0
47
520
10
0
43
520
10
0
41
506
—
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.5e-01
9.1e-01
—
—
—
3.6e-01
—
cases:13.21%
controls:11.54%
cases:13.21%
controls:5.77%
—
—
—
—
—
—
cases:11.76%
controls:8.50%
—
—
7
60
46
460
7
30
46
490
—
—
—
6
43
45
463
—
Three-surface restoration
SFA30 [2001310360]
2.5e-01
—
—
—
—
—
—
cases:11.32%
controls:9.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
47
47
473
—
—
—
—
—
—
ABO and Rh group [Type] in Blood
882-1 [3003694]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
—
0
9
51
497
—
Intraoral radiographic dental examination
EB1AA [2001301903]
3.1e-01
6.0e-01
—
—
—
1.3e+00
—
cases:15.09%
controls:11.54%
cases:9.43%
controls:5.38%
—
—
—
—
—
—
cases:11.76%
controls:3.56%
—
—
8
60
45
460
5
28
48
492
—
—
—
6
18
45
488
—
Left ventricular failure
I50.1 [45543181]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Pain in thoracic spine
M54.6 [45606247]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
53
503
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Cathetrisation of pulmonal artery
TFB00 [2001302495]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
felodipine; oral
C08CA02 [21601748]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
0
6
53
514
—
—
Other specified special examinations
Z01.8 [45581003]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
53
508
—
—
—
—
—
—
Fracture of rib
S22.3 [45573285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.88%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:2.17%
—
—
0
15
53
505
0
5
53
515
—
—
—
0
11
51
495
—
atorvastatin; oral
C10AA05 [21601860]
—
-3.7e-01
—
—
—
-1.9e-01
—
—
—
cases:9.43%
controls:13.08%
—
—
—
—
—
—
cases:11.76%
controls:13.83%
—
—
—
5
68
48
452
—
—
—
6
70
45
436
—
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
-1.3e-01
8.1e-01
—
—
—
8.3e-02
—
cases:11.32%
controls:12.69%
cases:13.21%
controls:6.35%
—
—
—
—
—
—
cases:9.80%
controls:9.09%
—
—
6
66
47
454
7
33
46
487
—
—
—
5
46
46
460
—
Old myocardial infarction
I25.2 [45601025]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
0
9
53
511
—
—
—
0
6
51
500
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.8e-01
—
—
—
—
-5.2e-02
—
cases:24.53%
controls:16.73%
—
—
—
—
—
—
—
—
cases:9.80%
controls:10.28%
—
—
13
87
40
433
—
—
—
—
5
52
46
454
—
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
0
6
53
514
—
—
—
0
6
51
500
—
Stroke/cerebrovascular accident
K90 [2002000617]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Other and unspecified convulsions
R56.8 [45602033]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
-2.1e-02
—
—
—
—
—
—
cases:11.32%
controls:11.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
60
47
460
—
—
—
—
—
—
fusidic acid; ointment
D06AX01 [21602062]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
Sensorineural hearing loss, bilateral
H90.3 [45576850]
1.2e+00
—
—
—
—
—
—
cases:15.09%
controls:5.00%
—
—
—
—
—
—
—
—
—
—
—
—
8
26
45
494
—
—
—
—
—
—
dabigatran etexilate; oral
B01AE07 [21601026]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
—
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
11
53
509
—
—
—
—
0
6
51
500
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Dental caries
K02 [45552906]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
3.7e-01
—
—
—
—
—
—
cases:11.32%
controls:8.08%
—
—
—
—
—
—
—
—
—
—
—
—
6
42
47
478
—
—
—
—
—
—
Plain photography of ocular fundus
CK2S4 [2001301455]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
0
5
53
515
—
—
—
0
5
51
501
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
6.8e-01
—
—
—
—
—
—
cases:13.21%
controls:7.12%
—
—
—
—
—
—
—
—
—
—
—
—
7
37
46
483
—
—
—
—
—
—
s-atenolol; oral
C07AB11 [21601693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Anaemia, unspecified
D64.9 [45600610]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
losartan; oral
C09CA01 [21601824]
3.6e-01
—
-1.0e+50
—
—
—
—
cases:13.21%
controls:9.62%
—
—
cases:0.00%
controls:3.46%
—
—
—
—
—
—
—
—
7
50
46
470
—
0
18
53
502
—
—
—
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
General Surgery
2 [38004447]
4.4e-01
—
—
—
—
—
—
cases:24.53%
controls:17.31%
—
—
—
—
—
—
—
—
—
—
—
—
13
90
40
430
—
—
—
—
—
—
brinzolamide, combinations
S01EC54 [45893490]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
0
5
53
515
0
5
53
515
—
—
—
0
7
51
499
—
Telephone prescription or other care instructions
WZB00 [2001310884]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
0
7
51
499
—
erdosteine; oral
R05CB15 [21603394]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
—
—
—
0
8
51
498
—
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
-1.1e-01
—
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:9.43%
controls:10.38%
—
—
cases:0.00%
controls:0.96%
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:4.55%
—
—
5
54
48
466
—
0
5
53
515
—
0
6
53
514
0
23
51
483
—
Spirometry study
18759-1 [3000492]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Heart disease other
K84 [2002000611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
pH of Capillary blood
2745-8 [3009343]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
7
53
513
—
—
—
—
0
5
51
501
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.7e-01
5.3e-01
—
—
—
5.4e-01
—
cases:26.42%
controls:18.27%
cases:16.98%
controls:10.77%
—
—
—
—
—
—
cases:21.57%
controls:13.83%
—
—
14
95
39
425
9
56
44
464
—
—
—
11
70
40
436
—
INR in Blood by Coagulation assay
34714-6 [3032080]
2.5e-01
9.0e-01
1.1e+00
—
1.1e+00
6.7e-01
—
cases:18.87%
controls:15.38%
cases:18.87%
controls:8.65%
cases:11.32%
controls:4.23%
—
—
cases:13.21%
controls:4.81%
cases:19.61%
controls:11.07%
—
—
10
80
43
440
10
45
43
475
6
22
47
498
—
7
25
46
495
10
56
41
450
—
Neurology
13 [38004458]
-9.5e-02
7.2e-01
—
—
—
5.8e-01
—
cases:11.32%
controls:12.31%
cases:9.43%
controls:4.81%
—
—
—
—
—
—
cases:9.80%
controls:5.73%
—
—
6
64
47
456
5
25
48
495
—
—
—
5
29
46
477
—
Retention of urine
R33 [45587507]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Intubation
WX704 [2001310820]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
Congestive heart failure
I50.0 [45567179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
—
budesonide; inhalant
R03BA02 [21603285]
7.7e-01
—
—
—
—
—
—
cases:9.43%
controls:4.62%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
48
496
—
—
—
—
—
—
gabapentin; oral
N02BF01 [955005]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
Aortic (valve) stenosis
I35.0 [45576869]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.92%
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
0
10
53
510
0
8
53
512
—
—
—
—
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
2.8e-02
9.9e-01
—
—
—
3.6e-02
—
cases:13.21%
controls:12.88%
cases:15.09%
controls:6.15%
—
—
—
—
—
—
cases:9.80%
controls:9.49%
—
—
7
67
46
453
8
32
45
488
—
—
—
5
48
46
458
—
Hyperplasia of prostate
N40 [45563015]
-2.1e-02
—
—
—
—
—
—
cases:9.43%
controls:9.62%
—
—
—
—
—
—
—
—
—
—
—
—
5
50
48
470
—
—
—
—
—
—
metformin; oral
A10BA02 [21600747]
-2.6e-01
-1.8e-01
—
—
-1.0e+50
-2.9e-01
—
cases:11.32%
controls:14.23%
cases:11.32%
controls:13.27%
—
—
—
—
cases:0.00%
controls:3.65%
cases:9.80%
controls:12.65%
—
—
6
74
47
446
6
69
47
451
—
—
0
19
53
501
5
64
46
442
—
Body temperature
8310-5 [3020891]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
candesartan; oral
C09CA06 [21601829]
4.3e-01
—
—
—
—
5.4e-01
—
cases:9.43%
controls:6.35%
—
—
—
—
—
—
—
—
cases:9.80%
controls:5.93%
—
—
5
33
48
487
—
—
—
—
5
30
46
476
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
53
507
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
—
0
12
53
508
—
—
—
—
—
combinations of corticosteroids
D07AB30 [21602118]
-4.0e-02
—
—
—
—
—
—
cases:11.32%
controls:11.73%
—
—
—
—
—
—
—
—
—
—
—
—
6
61
47
459
—
—
—
—
—
—
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Hearing loss, unspecified
H91.9 [45547996]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Memory disturbance
P20 [2002000816]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.31%
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
12
53
508
0
7
53
513
—
—
—
0
5
51
501
—
tafluprost
S01EE05 [21603714]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
6
53
514
0
6
53
514
—
—
—
0
6
51
500
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.69%
—
—
—
—
—
—
—
—
—
—
—
0
14
53
506
—
—
—
—
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
—
—
—
—
—
0
10
51
496
—
ofloxacin; oral, parenteral
J01MA01 [21603008]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
metformin and sitagliptin
A10BD07 [21600772]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Epistaxis
R04.0 [45606791]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
ramipril; oral
C09AA05 [21601789]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
0
11
53
509
—
0
7
53
513
—
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
53
497
—
—
—
—
—
—
hydrocortisone
D07AA02 [21602102]
2.7e-01
-1.0e+50
—
—
—
—
—
cases:11.32%
controls:8.85%
cases:0.00%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
6
46
47
474
0
12
53
508
—
—
—
—
—
Urology
34 [38004474]
2.4e-01
—
—
—
—
8.9e-01
—
cases:15.09%
controls:12.31%
—
—
—
—
—
—
—
—
cases:13.73%
controls:6.13%
—
—
8
64
45
456
—
—
—
—
7
31
44
475
—
Other disorders of vitreous body
H43.8 [45533329]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
Body mass index
60621009 [4245997]
-3.7e-01
—
—
—
—
—
—
cases:16.98%
controls:22.88%
—
—
—
—
—
—
—
—
—
—
—
—
9
119
44
401
—
—
—
—
—
—
Microlaryngoscopy
UDQ22 [2001301828]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:11.32%
controls:0.00%
—
—
—
—
—
—
—
—
—
6
0
47
520
—
—
—
Laboratory test
15220000 [4034850]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.46%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
0
18
53
502
0
6
53
514
—
—
—
0
7
51
499
—
Hypertension uncomplicated
K86 [2002000613]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
—
—
—
—
—
0
10
51
496
—
phenylephrine, combinations
R01BA53 [21603214]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Occupational therapy
R4120 [2001310234]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:2.77%
—
—
—
0
7
53
513
—
—
—
0
14
51
492
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.0e-02
8.3e-02
—
—
—
1.4e-01
—
cases:37.74%
controls:36.35%
cases:20.75%
controls:19.42%
—
—
—
—
—
—
cases:25.49%
controls:22.92%
—
—
20
189
33
331
11
101
42
419
—
—
—
13
116
38
390
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:5.00%
—
—
—
—
—
—
—
—
—
—
—
0
26
53
494
—
—
—
—
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
-1.1e-01
3.7e-01
—
—
—
—
—
cases:9.43%
controls:10.38%
cases:9.43%
controls:6.73%
—
—
—
—
—
—
—
—
—
—
5
54
48
466
5
35
48
485
—
—
—
—
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:9.80%
controls:3.16%
—
—
—
—
—
—
—
5
16
46
490
—
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
Teeth/gum disease
D82 [2002000380]
6.0e-01
—
—
—
—
—
—
cases:9.43%
controls:5.38%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
48
492
—
—
—
—
—
—
telmisartan; oral
C09CA07 [21601830]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
Atrioventricular block, complete
I44.2 [45576872]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Lyme disease
A69.2 [45595594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Other primary gonarthrosis
M17.1 [45596493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
5.4e-01
—
—
—
—
—
—
cases:11.32%
controls:6.92%
—
—
—
—
—
—
—
—
—
—
—
—
6
36
47
484
—
—
—
—
—
—
Enzyme measurement
122444009 [4046263]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
53
507
—
—
—
—
—
—
Plastic And Reconstructive Surgery
24 [38004467]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
0
9
53
511
—
—
—
0
9
51
497
—
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
-1.3e-02
-2.9e-01
—
—
—
-3.5e-01
—
cases:20.75%
controls:20.96%
cases:15.09%
controls:19.23%
—
—
—
—
—
—
cases:15.69%
controls:20.95%
—
—
11
109
42
411
8
100
45
420
—
—
—
8
106
43
400
—
Contusion of thorax
S20.2 [45597402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Biopsy of larynx
DQA10 [2001301842]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:13.21%
controls:0.00%
—
—
—
—
—
—
—
—
—
7
0
46
520
—
—
—
Repair work or maintenance done on the aid
R5130 [2001310248]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
-3.3e-01
—
—
—
—
—
—
cases:9.43%
controls:12.69%
—
—
—
—
—
—
—
—
—
—
—
—
5
66
48
454
—
—
—
—
—
—
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.73%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.58%
—
—
0
9
53
511
0
6
53
514
—
—
—
0
8
51
498
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
4.3e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:9.43%
controls:6.35%
cases:0.00%
controls:2.31%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
5
33
48
487
0
12
53
508
—
—
—
0
12
51
494
—
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.31%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
—
0
12
53
508
—
—
—
0
12
51
494
—
Protein [Mass/volume] in Urine
2888-6 [3037121]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
7
53
513
—
—
—
—
0
5
51
501
—
Anaemia vit B12/folate deficiency
B81 [2002000292]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
0
8
53
512
0
6
53
514
—
—
—
0
7
51
499
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:13.73%
controls:3.36%
—
—
—
—
—
—
—
7
17
44
489
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.9e-02
5.8e-01
1.4e+00
—
—
8.0e-02
—
cases:35.85%
controls:35.19%
cases:32.08%
controls:20.96%
cases:11.32%
controls:3.08%
—
—
—
—
cases:27.45%
controls:25.89%
—
—
19
183
34
337
17
109
36
411
6
16
47
504
—
—
14
131
37
375
—
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
8
53
512
—
—
—
—
0
6
51
500
—
Chest pain NOS
A11 [2002000152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
—
Skin symptom/complaint other
S29 [2002000993]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
53
507
—
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
1.7e-01
1.2e-01
—
—
—
2.0e-01
—
cases:13.21%
controls:11.35%
cases:9.43%
controls:8.46%
—
—
—
—
—
—
cases:11.76%
controls:9.88%
—
—
7
59
46
461
5
44
48
476
—
—
—
6
50
45
456
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.31%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
12
53
508
0
5
53
515
—
—
—
—
—
digoxin; oral, parenteral
C01AA05 [21600234]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.50%
—
—
—
—
—
—
cases:0.00%
controls:2.77%
—
—
—
0
13
53
507
—
—
—
0
14
51
492
—
aciclovir; oral, parenteral
J05AB01 [21603131]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
Other administrative function
SPAT1281 [2001700382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
indometacin
C01EB03 [21600365]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
53
513
—
—
—
—
—
—
sulfasalazine; oral, rectal
A07EC01 [21600663]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.73%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
9
53
511
0
5
53
515
—
—
—
—
—
macrogol; oral
A06AD15 [21600575]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
—
Non-insulin dependent diabetes diabetic hypoglycaemic coma
E11.00 [2000501437]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
—
—
—
—
0
9
51
497
—
Scheduled procedure
ZXD10 [2001311387]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
7.0e-01
—
—
—
—
—
—
cases:11.32%
controls:5.96%
—
—
—
—
—
—
—
—
—
—
—
—
6
31
47
489
—
—
—
—
—
—
amitriptyline and psycholeptics
N06CA01 [21604789]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.35%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
7
53
513
0
5
53
515
—
—
—
—
—
fluticasone furoate; nasal
R01AD12 [21605053]
7.8e-01
—
—
—
—
—
—
cases:13.21%
controls:6.54%
—
—
—
—
—
—
—
—
—
—
—
—
7
34
46
486
—
—
—
—
—
—
Diabetes, non-insulin-treated
215 [2001600211]
4.5e-01
—
—
—
—
—
—
cases:11.32%
controls:7.50%
—
—
—
—
—
—
—
—
—
—
—
—
6
39
47
481
—
—
—
—
—
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
2.7e-01
1.0e+00
—
—
—
3.1e-01
—
cases:15.09%
controls:11.92%
cases:15.09%
controls:5.96%
—
—
—
—
—
—
cases:11.76%
controls:8.89%
—
—
8
62
45
458
8
31
45
489
—
—
—
6
45
45
461
—
Primary gonarthrosis, bilateral
M17.0 [45562648]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
0
7
53
513
—
—
—
0
6
51
500
—
Pulmonary Disease
29 [38004472]
8.0e-01
8.4e-01
1.9e+00
—
—
1.0e+00
—
cases:18.87%
controls:9.42%
cases:11.32%
controls:5.19%
cases:9.43%
controls:1.54%
—
—
—
—
cases:13.73%
controls:5.34%
—
—
10
49
43
471
6
27
47
493
5
8
48
512
—
—
7
27
44
479
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
0
5
53
515
—
—
—
0
5
51
501
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:3.85%
—
—
—
—
—
—
—
—
—
—
—
0
20
53
500
—
—
—
—
—
Dermatitis/atopic eczema
S87 [2002001051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Left side
ZXA05 [2001311347]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
25
53
495
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
-1.2e-01
—
—
—
—
—
—
cases:13.21%
controls:14.62%
—
—
—
—
—
—
—
—
—
—
—
—
7
76
46
444
—
—
—
—
—
—
Perimetry
XCK00 [2001301380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.9e-01
9.4e-01
—
—
—
8.9e-01
—
cases:16.98%
controls:13.27%
cases:13.21%
controls:5.58%
—
—
—
—
—
—
cases:15.69%
controls:7.11%
—
—
9
69
44
451
7
29
46
491
—
—
—
8
36
43
470
—
Eye symptom/complaint other
F29 [2002000412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
calcium (different salts in combination); oral
A12AA20 [21600872]
1.7e-01
—
—
—
—
5.5e-01
—
cases:9.43%
controls:8.08%
—
—
—
—
—
—
—
—
cases:11.76%
controls:7.11%
—
—
5
42
48
478
—
—
—
—
6
36
45
470
—
Thorax X-ray examination
GD1AA [2001303617]
-1.5e-01
1.2e+00
—
—
—
—
—
cases:11.32%
controls:12.88%
cases:9.43%
controls:3.08%
—
—
—
—
—
—
—
—
—
—
6
67
47
453
5
16
48
504
—
—
—
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
6.3e-02
4.8e-01
—
—
—
—
—
cases:13.21%
controls:12.50%
cases:11.32%
controls:7.31%
—
—
—
—
—
—
—
—
—
—
7
65
46
455
6
38
47
482
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.1e+00
—
—
—
—
—
—
cases:11.32%
controls:4.04%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
47
499
—
—
—
—
—
—
Melanocytic naevi of trunk
D22.5 [45542688]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
ebastine; oral
R06AX22 [21603521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
—
Cardiac arrhythmia, unspecified
I49.9 [45581778]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
7.4e-02
—
—
—
—
5.1e-01
—
cases:16.98%
controls:15.96%
—
—
—
—
—
—
—
—
cases:9.80%
controls:6.13%
—
—
9
83
44
437
—
—
—
—
5
31
46
475
—
beclometasone; nasal
R01AD01 [21605043]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Emergency Medicine
93 [38004510]
2.7e-01
1.1e+00
—
—
—
8.4e-01
—
cases:16.98%
controls:13.46%
cases:16.98%
controls:6.35%
—
—
—
—
—
—
cases:19.61%
controls:9.49%
—
—
9
70
44
450
9
33
44
487
—
—
—
10
48
41
458
—
Periodontitis pronounced
K05.31 [2000502729]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.88%
cases:0.00%
controls:1.92%
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
0
15
53
505
0
10
53
510
—
—
—
0
6
51
500
—
Orthostatic test
SPAT1101 [2001700202]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
Vascular Surgery
77 [38004496]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
Cough
R05 [2002000886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:3.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
53
501
—
—
—
—
—
—
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
0
8
53
512
0
6
53
514
—
—
—
0
5
51
501
—
tadalafil; oral
G04BE08 [21602653]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
cases:0.00%
controls:1.78%
—
—
—
0
7
53
513
—
—
—
0
9
51
497
—
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
furosemide; oral, parenteral
C03CA01 [21601518]
1.7e-02
—
-1.0e+50
—
—
—
—
cases:11.32%
controls:11.15%
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
6
58
47
462
—
0
10
53
510
—
—
—
—
carvedilol; oral
C07AG02 [21601700]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
PEF monitoring instruction
SPAT1058 [2001700159]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
53
509
—
—
—
—
—
—
Other physical therapy
Z50.1 [45600331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.54%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
8
53
512
0
5
53
515
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.3e-01
1.4e-01
—
—
—
1.5e-01
—
cases:22.64%
controls:20.38%
cases:9.43%
controls:8.27%
—
—
—
—
—
—
cases:13.73%
controls:12.06%
—
—
12
106
41
414
5
43
48
477
—
—
—
7
61
44
445
—
sotalol; oral, parenteral
C07AA07 [21601672]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
6
53
514
0
5
53
515
—
—
—
—
—
Electrocardiogram with exercise test
46136006 [4261794]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.69%
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
0
14
53
506
0
5
53
515
—
—
—
—
—
Gastroenterology
10 [38004455]
2.8e-01
—
—
—
—
—
—
cases:9.43%
controls:7.31%
—
—
—
—
—
—
—
—
—
—
—
—
5
38
48
482
—
—
—
—
—
—
quetiapine; oral
N05AH04 [21604544]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:1.78%
—
—
—
0
11
53
509
—
—
0
6
53
514
0
9
51
497
—
Issue of medical certificate
Z02.7 [45537613]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
53
506
—
—
—
—
—
—
Iron deficiency anaemia, unspecified
D50.9 [45605373]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
0
6
53
514
0
6
53
514
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
-1.3e-01
8.7e-01
—
—
—
1.1e-01
—
cases:11.32%
controls:12.69%
cases:13.21%
controls:5.96%
—
—
—
—
—
—
cases:9.80%
controls:8.89%
—
—
6
66
47
454
7
31
46
489
—
—
—
5
45
46
461
—
Handing over of treatment supplies
SPAT1262 [2001700363]
—
1.1e+00
—
—
—
—
—
—
—
cases:9.43%
controls:3.46%
—
—
—
—
—
—
—
—
—
—
—
5
18
48
502
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
9.5e-02
—
—
—
—
—
—
cases:9.43%
controls:8.65%
—
—
—
—
—
—
—
—
—
—
—
—
5
45
48
475
—
—
—
—
—
—
Ambulatory ECG
XF404 [2001303370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
53
510
—
—
—
—
—
—
General Practice
1 [38004446]
-3.5e-01
4.6e-01
—
—
—
1.3e+00
—
cases:11.32%
controls:15.38%
cases:9.43%
controls:6.15%
—
—
—
—
—
—
cases:17.65%
controls:5.73%
—
—
6
80
47
440
5
32
48
488
—
—
—
9
29
42
477
—
hydroxocobalamin
V03AB33 [21605256]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.12%
cases:0.00%
controls:1.54%
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
0
11
53
509
0
8
53
512
—
—
—
0
10
51
496
—
nepafenac
S01BC10 [21603648]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
6
51
500
—
Telehealth
OMOP5556618 [722455]
-2.4e-01
-3.7e-01
—
—
—
—
—
cases:24.53%
controls:29.23%
cases:11.32%
controls:15.58%
—
—
—
—
—
—
—
—
—
—
13
152
40
368
6
81
47
439
—
—
—
—
—
Acute tubulo-interstitial nephritis
N10 [45543856]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
codeine and paracetamol
N02AJ06 [1123647]
3.4e-01
—
—
—
—
—
—
cases:18.87%
controls:14.23%
—
—
—
—
—
—
—
—
—
—
—
—
10
74
43
446
—
—
—
—
—
—
General symptom/complaint other
A29 [2002000163]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
0
8
53
512
—
—
—
—
—
hydrocortisone
S02BA01 [21605166]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
Thorax CT examination
GD1AD [2001303618]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
0
5
51
501
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
5.7e-01
—
—
—
—
-1.0e+50
—
cases:11.32%
controls:6.73%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
6
35
47
485
—
—
—
—
0
10
51
496
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
53
497
—
—
—
—
—
—
Hand Surgery
40 [38004480]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.98%
—
—
—
—
—
—
—
0
10
51
496
—
Pharmacy visit
OMOP4822462 [581458]
-2.8e-02
2.7e-01
3.0e-01
—
6.7e-01
4.6e-01
—
cases:86.79%
controls:87.12%
cases:84.91%
controls:81.15%
cases:62.26%
controls:55.00%
—
—
cases:64.15%
controls:47.88%
cases:88.24%
controls:82.61%
—
—
46
453
7
67
45
422
8
98
33
286
20
234
—
34
249
19
271
45
418
6
88
—
More than five and less than seven hours
ZXE30 [2001311411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
—
Chloride [Moles/volume] in Blood
2069-3 [3018572]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
Carcinoma in situ of respiratory system, Larynx
2310A [2000402164]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:11.32%
controls:0.00%
—
—
—
—
—
—
—
—
—
6
0
47
520
—
—
—
Ultrasound measurement of residual urine
KC1EE [2001305918]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
9
53
511
—
—
—
—
—
Cardiovascular stress test using bicycle ergometer
26046004 [4094501]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
53
514
—
—
—
—
—
—
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.55%
—
—
—
—
—
—
—
0
23
51
483
—
Organisation of medication
SPAT1251 [2001700352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
53
515
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
159
3.42
4.77
3.8
2.1
—
—
—
0
0
37
232
2.82
3.22
5.5
9.2
1.22
1.20
mmol/l
1.19
30
202
29
162
2.67
3.15
7.3
4.7
—
—
—
0
0
10
35
3.26
2.35
4.4
4.3
—
—
—
0
0
50
408
3.47
2.33
26.6
17.9
—
—
—
0
0
30
190
2.27
2.28
8.2
6.2
0.40
0.57
%
1.03
25
173
37
260
2.29
2.14
7.1
7.5
12.63
11.80
umol/l
0.13
37
252
32
215
2.17
2.03
6.5
4.8
49.43
38.61
ng/l
0.19
27
174
30
200
2.10
1.91
8.6
6.2
25.33
24.31
%
0.18
25
185
39
290
2.19
1.83
4.0
4.9
—
—
—
0
0
25
163
1.98
1.63
5.1
4.7
—
—
—
0
0
10
46
2.43
1.50
1.9
4.2
0.00
0.14
%
—
5
14
13
70
2.12
1.38
1.8
2.1
—
—
—
0
0
19
120
1.89
1.31
2.7
3.8
402.46
352.66
umol/l
0.72
13
103
28
201
1.80
1.29
3.0
2.8
—
—
estimate
—
0
0
8
37
2.36
1.28
5.5
6.1
1.19
1.22
mmol/l
—
8
32
19
122
1.85
1.24
3.5
3.8
0.00
0.00
estimate
—
9
45
24
166
1.79
1.24
4.5
4.1
4.43
12.05
mg/mmol
1.40
13
109
12
66
2.05
1.20
2.7
2.9
1.66
1.83
%
0.27
12
59
10
51
2.17
1.20
1.9
4.0
0.40
1.16
%
—
5
19
7
36
2.08
1.01
1.0
1.5
—
—
—
0
0
9
51
1.91
1.00
2.4
2.6
70.97
66.32
e9/l
—
9
40
0
31
0.00
1.00
0.0
6.2
—
96.74
—
0
25
14
87
1.82
0.99
3.9
7.5
—
—
—
0
0
22
158
1.65
0.95
3.2
3.3
64.62
78.29
mg/l
0.09
13
109
31
244
1.62
0.93
3.0
4.5
0.00
27.07
estimate
0.49
11
60
21
150
1.65
0.92
3.3
4.4
0.00
0.04
estimate
—
9
54
21
150
1.65
0.92
2.4
2.6
—
—
—
0
0
8
43
2.00
0.92
2.1
4.9
67.95
66.48
g/l
—
8
38
8
43
2.00
0.92
1.6
1.2
—
—
—
0
0
20
145
1.60
0.82
9.2
5.6
—
—
—
0
0
9
56
1.72
0.77
2.7
4.3
2.69
2.49
mmol/l
—
9
48
26
203
1.53
0.76
2.5
2.4
97.04
84.82
pmol/l
0.86
19
117
30
242
1.53
0.76
3.0
4.5
0.00
0.00
estimate
-0.00
12
59
9
58
1.66
0.74
1.7
1.8
—
—
—
0
0
44
390
1.64
0.69
4.8
5.5
1.40
1.38
mmol/l
0.08
38
345
8
50
1.70
0.65
1.9
2.1
5.93
13.45
nmol/l
—
8
45
30
248
1.46
0.64
3.0
4.5
0.00
0.00
estimate
-0.00
11
52
15
108
1.53
0.61
2.5
3.4
591.50
539.16
mosm/kgh2o
—
10
96
0
21
0.00
0.61
0.0
1.0
—
—
—
0
0
6
34
1.86
0.61
2.3
1.8
—
—
—
0
0
23
184
1.43
0.56
3.2
4.7
0.00
0.06
estimate
—
10
49
27
317
0.71
0.55
27.3
27.1
333.19
331.47
g/l
0.74
27
317
12
85
1.53
0.52
4.3
4.1
0.78
0.79
mmol/l
0.09
12
80
7
49
1.49
0.48
1.9
1.3
—
—
—
0
0
8
56
1.50
0.45
1.5
1.2
—
—
—
0
0
5
32
1.62
0.43
2.4
3.1
0.52
0.65
%
—
5
32
5
32
1.62
0.43
2.4
3.2
1.86
1.07
%
—
5
32
15
116
1.40
0.43
4.8
3.9
—
—
—
0
0
0
18
0.00
0.40
0.0
18.9
—
—
—
0
0
6
89
0.63
0.36
2.5
8.3
102.50
103.85
mmol/l
—
6
89
7
55
1.31
0.31
1.4
1.3
—
—
—
0
0
7
90
0.75
0.25
3.3
3.0
11.36
11.80
umol/l
—
7
84
5
41
1.24
0.22
2.6
4.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
9.73
—
0
11
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.25
0.21
2.3
12.7
—
—
—
0
0
7
89
0.76
0.16
3.0
3.0
2.28
2.22
g/l
—
7
82
17
154
1.15
0.12
4.2
2.3
327.41
152.21
u/l
0.66
17
146
12
135
0.86
0.11
9.8
7.1
—
—
—
0
0
5
46
1.10
0.10
1.4
1.6
—
—
—
0
0
6
58
1.04
0.09
1.3
4.5
4.92
77.11
ug/l
—
6
50
6
73
0.80
0.08
4.3
9.2
7.43
7.42
ph
—
6
42
20
188
1.10
0.07
2.8
4.2
5.90
6.29
ph
1.69
15
103
16
151
1.08
0.04
3.6
3.5
0.86
0.75
ug/l
0.47
11
114
20
193
1.06
0.01
3.2
4.2
260.23
89.08
e6/l
0.37
15
149
15
149
1.01
0.00
2.1
3.5
—
—
—
0
0
11
105
1.06
0.00
2.1
1.4
—
—
—
0
0
14
136
1.04
0.00
6.8
5.9
7.39
7.40
ph
0.34
14
99
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
-0.27
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
216.00
—
0
7
5
50
1.00
-0.00
1.2
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
54
0.92
-0.00
1.0
2.5
5.48
5.00
ug/l
—
5
49
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_LARYNX – Carcinoma in situ of larynx

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).